ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
ELITE PHARMACEUTICALS INC /NV/ revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviated New Drug Applications [Member] | – | – | – | – | $40.21M | $32.00M | $14.36M | $18.88M | $18.80M | $17.95M | $15.54M | $14.16M | – | – |
| New Drug Applications [Member] | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
| Operating income | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Segment [Member] | – | – | $11.91M | $12.69M | $25.55M | $15.25M | $4.33M | $6.23M | $6.31M | $6.40M | $5.64M | $3.83M | – |
| Abbreviated New Drug Applications [Member] | – | – | $11.91M | $12.69M | $25.55M | $15.25M | $4.33M | $6.23M | $6.31M | $6.40M | $5.64M | $3.83M | – |
| New Drug Applications [Member] | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANDA Revenue [Member] | $32.13M | – | – | – | $39.78M | – | – | – | – | – | – | – | 99.3% | -19.2% |
| Scheduled Products Manufacturing Fees [Member] | $27.81M | – | – | – | $38.91M | – | – | – | – | – | – | – | 86.0% | -28.5% |
| Direct Sales to Wholesalers [Member] | $16.40M | – | – | – | $19.03M | – | – | – | – | – | – | – | 50.7% | -13.8% |
| Indirect Sales to Wholesalers [Member] | $15.73M | – | – | – | $20.75M | – | – | – | – | – | – | – | 48.6% | -24.2% |
| Unscheduled Products Manufacturing Fees [Member] | $4.32M | – | – | – | $863.88K | – | – | – | – | – | – | – | 13.4% | +400.6% |
| Licensing [Member] | $220.96K | $295.65K | $205.57K | $125.45K | $433.33K | $417.43K | $626.12K | $655.16K | $359.15K | $36.55K | $747.69K | $649.32K | 0.7% | -49.0% |
| Scheduled Products Licensing Fees [Member] | $220.96K | – | – | – | – | – | – | – | – | – | – | – | 0.7% | – |
| Manufacturing [Member] | – | $40.45M | $31.38M | $36.20M | $39.78M | $31.58M | $13.74M | $18.23M | $18.44M | $17.91M | $14.79M | $13.51M | – | – |
| Unscheduled Products Licensing Fees [Member] | – | – | – | – | $433.33K | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Elite Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.